Syngene targets delivering 500,000 vials of remdesivir in India in May - executive

Syngene International

28/04/2021 12:53

BENGALURU, April 28 (Reuters) - India's Syngene
International Ltd  SYNN.NS  is aiming to deliver half a million
vials of COVID-19 drug remdesivir through its distribution
partners to the Indian market next month, its Chief Executive
Officer told Reuters on Wednesday.
    The company, which offers research and manufacturing
services on a contractual basis to drugmakers across the world,
has been supplying the drug in India under a licensing agreement
with U.S.-based Gilead Sciences Inc  GILD.O . 
    It did not provide details on how many vials it has already
delivered.
          

 (Reporting by Anuron Kumar Mitra in Bengaluru)
 ((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))